rare but serious optic nerve condition that can lead to sudden, painless vision loss in one eye. The loss may be partial or permanent, and patients might notice symptoms such as blind spots, tunnel vision, color distortion, or hazy central vision. The FDA’s new requirement adds this potential NAION risk to the Warnings and Precautions section for all GLP-1 RA products, not just one or two drugs. This means clinicians and patients will see a consistent message across the class, from injectable agents such as liraglutide and dulaglutide to oral